Webcast Today - New Data from bioMUSE Natural History Study
Released
Released
Announcement PDF
Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE
Natural History Study
- New bioMUSE Data Informs ATH434-202 Study Endpoints –
- Webcast to Include Key Opinion Leader, Daniel Claassen, M.D., M.S., Vanderbilt University MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 30 May 2024: Alterity Therapeutics (ASX:
ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to
developing disease modifying treatments for neurodegenerative diseases, will be hosting an
investor webcast today on Thursday, 30 May 2024 in Australia / Wednesday, 29 May 2024 in the
United States. Details are listed below and registration is required.
The call will feature Alterity’s CEO Dr. David Stamler who will discuss the bioMUSE Natural History
Study results and their impact on the endpoints for the ATH434-202 Phase 2 clinical trial. Joining
the call will be key opinion leader Daniel Claassen, M.D., M.S., Professor of Neurology, Vanderbilt
University Medical Center. Dr. Claassen is the Principal Investigator of bioMUSE and the
Coordinating Investigator of the ATH434-201 Phase 2 clinical trial.
Webcast details
AUSTRALIA PARTICIPANTS:
Date: Thursday, 30 May 2024
Time: 10:00 a.m. AEST (Sydney/Melbourne)
UNITED STATES PARTICIPANTS:
Date: Wednesday, 29 May 2024
Time: 5:00 p.m. Pacific Time
8:00 p.m. Eastern Time
Register for the Zoom webcast: https://bit.ly/3yFXHMp
Registration is required and dial in details will be sent directly upon registration.
Investors will have the opportunity to ask questions during the call, at the conclusion of the
presentation. Investors are also able to submit questions in advance to Hannah Howlett at weaualteritytherapeutics@we-worldwide.com
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate
future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has
the potential to treat various Parkinsonian disorders and is currently being evaluated in two
Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery
platform generating patentable chemical compounds to treat the underlying pathology of
neurological diseases. The Company is based in Melbourne, Australia, and San Francisco,
California, USA. For further information please visit the Company’s website at
www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Investor and Media Contacts:
Australia
Hannah Howlett
we-aualteritytherapeutics@we-worldwide.com
+61 450 648 064
U.S.
Remy Bernarda
remy.bernarda@iradvisory.com
+1 (415) 203-6386
David Stamler, MD
Webinar – bioMUSE Data Release
CEO
May 29/30, 2024
Forward Looking Statements
This presentation may contain some statements that
may be considered “Forward-Looking Statements”,
within the meaning of the US Securities Laws. Thus,
any forward-looking statement relating to financial
projections or other statements relating to the
Company’s plans, objectives, expectations or intentions
involve risks and uncertainties that may cause actual
results to differ materially. For a discussion of such
risks and uncertainties as they relate to us, please refer
to our 2023 Form 20-F, filed with US Securities and
Exchange Commission, in particular Item 3, Section D,
titled “Risk Factors.’’
2
Objectives of Today’s Webinar
•
•
•
•
Review new data from bioMUSE natural history study
Discuss relevance of bioMUSE for ATH434-202 study
Expert perspective on Multiple System Atrophy (MSA)
Review timing of Phase 2 data
3
Promising Portfolio in Neurodegenerative Diseases
ASSET
PHASE
DISCOVERY
PRECLINICAL
NATURAL
HISTORY
PARTNER
PROGRAM
INDICATION
ATH434-201
Multiple System Atrophy
Early Stage
Enrollment Complete
ATH434-202
Multiple System Atrophy
Advanced
Enrollment Complete
ATH434
Parkinson’s Disease
bioMUSE
Multiple System Atrophy
Natural History Study
Drug
Discovery
Neurodegenerative
Diseases
PHASE 1
PHASE 2
PARTNER /
COLLABORATOR
4
Multiple System Atrophy (MSA): Rare, Highly Debilitating and
Rapidly Progressive Neurodegenerative Disease
• Parkinsonian disorder with no approved
treatment
• Orphan disease
• Disease characteristics
• Motor: Parkinsonism, uncoordinated movements,
balance problems/falls
• Autonomic dysfunction: blood pressure
maintenance, bladder control, bowel function
• Brain atrophy in multiple regions
Death can occur
Clinically Established MSA
Premotor MSA
• Median survival 7.5 years after symptom
onset
. Mov Disorders 2022 | Coon, et al. Brain 2015 | Claassen,et al. Mov Disorders 2021
Sources: Fanciulli, Wenning. NEJM 2015 | Wenning, et al
Clinically Probable MSA
0
3
Years
6
9
5
Iron is Critical in Disease Pathogenesis
Iron and α-Synuclein are important
contributors to MSA pathology
Oxidative Stress
• Adverse impact of excess labile iron
• Leads to α-synuclein aggregation à neuronal
dysfunction
• Oxidative stress with intracellular damage
• Cell death
Stored iron
• Hallmark of MSA pathology
• α-synuclein aggregates in neurons and glial
(support) cells
• Neuron and glial cells loss
• Atrophy in multiple brain regions
Neuroinflammation
Iron Imbalance
Labile iron
• Needed for cellular
metabolism
• Generates damaging
free radicals
6
Sources: Kaindlstorfer, J. Alzheimers Dis. 2018; Bengoa-Vergniory N, Acta Neuropathol. 2017
Accumulated Evidence of ATH434 Efficacy
Midbrain*
Iron
α-Synuclein
Preserve Neurons/
Function
Clinical Observations
Mouse MPTP
â
â
á
Improved motor
performance
Parkinson’s disease
Mouse A53T
â
â
á
Improved motor
performance
Parkinson’s disease
Mouse tau knockout
â
â
á
Improved motor
performance
MSA
PLP-α-syn
â
â
á
Improved motor
performance
MSA
PLP-α-syn
â
â
á
Improved motor
performance
Parkinson’s disease
Monkey MPTP
â
n/a
á
Improved motor
performance
Target Disease
Model
Parkinson’s disease
* includes s. nigra
ATH434 consistently improved motor performance across diverse animal models of disease
by redistributing iron and preserving neurons
7
Source: Finkelstein, Acta Neuropath Comm 2017; Beauchamp et al, Neurotherapeutics 2022; Heras-Garvin et al, Mov Disord. 2021; Finkelstein et al, J Park Dis 2022; Bradbury et al, Am Acad. Neurol 2024
Approach: Address Underlying Pathology of Disease
Redistribute excess
labile iron
in the CNS
Reduce α-synuclein
aggregation
and
Rescue brain cells/
neuronal function
Oxidative stress
Potential Disease Modifying Therapy for MSA
8
Multiple System Atrophy
Clinical Development Program
9
Clinical Studies in MSA
Study
bioMUSE – Natural History
ATH434-201 – Phase 2
ATH434-202 – Phase 2
Design
Observational
Randomized, double-blind
Single arm, open-label
Objectives
Characterize early-stage MSA
Efficacy and safety of ATH434
Efficacy and safety of ATH434
Population
Early-stage MSA
Early-stage MSA
Advanced MSA
Sample Size
N = 21
N = 77
N = 10
Observation/Treatment
12 months
12 months treatment
12 months treatment
Brain MRI Biomarkers
Iron, volume, glial pathology
Same as bioMUSE
Same as bioMUSE
Fluid Biomarkers
NFL, Aggregated α-synuclein
Same as bioMUSE
Same as bioMUSE
Other Biomarkers
Wearable movement sensors
Same as bioMUSE
─
Clinical Measures
Motor exam, autonomic
function, activities of daily
living, global measures
Motor exam, autonomic and
Same as bioMUSE
Observation exam, autonomic
Motor exam, autonomic and
Same as bioMUSE
Observation exam, autonomic
10
BioMUSE Natural History Study
Learnings to Date
Advanced MRI methods
α-synuclein in CSF
Fluorescence
1000000
Optimize Patient
Selection
100000
PD
10000
MSA
1000
100
Revised selection criteria in
ATH434-201 and ATH434-202
protocols to exclude PD patients
Time →
Differentiate MSA from PD
0
Iron content [ppb]
300
Identify “iron signature”
of early MSA
New MRI Template
Iron distribution in MSA
Precision Endpoint
Assessment
State of the art methods enabled
precise measurements of iron
and brain volume with MRI
Improve precision of
structural MRI
Sources: Presentations/Posters on file, including Claassen et al, MDS Conference 2021 and 2022.
Novel strategies for measuring
brain iron in individual regions
11
Participant Flow in bioMUSE
25 Adults 30 to 78 yo with MSA
assessed for eligibility
4 Excluded
• 2 Unable to complete procedures
• 1 Exclusionary MRI findings
• 1 Unreliable
21 Enrolled
17 Early Stage
(Clinically Probable MSA)
10 MSA
5 Parkinson
2 Undefined
4 Advanced
(Clinically Established MSA)
Single timepoint
Ô
Refine biomarker endpoints
Followed for 12 months
Source
13
BioMUSE Brain Imaging Biomarkers
Assessed in MSA Regions
Biomarker
How Assessed
Status
Iron content
MRI/QSM
12 mo data reported today
Volumes
MRI/T1w
12 mo data reported today
N-acetylaspartate/
myoinositol
MR spectroscopy
Preliminary data reported in 2023
Neuromelanin
MRI
In process
14
MRI Methods to Measure Brain Iron
• Based on routine (e.g., structure/volume) and specialized MRI techniques
• Bioengineer evaluated MRI processing algorithms to optimize measurement1,2
• Method selected which is reproducible and minimizes artifacts between MRIs
We have established standardized methods to analyze brain iron in bioMUSE
and will apply same methods in the Phase 2 studies
15
Marques. QSM reconstruction challenge 2.0. Magn Reson Med. 2021
2 QSM consensus Committee. Recommended implementation of QSM. Magn Reson Med. 2024
1
BioMUSE: Change in Iron Content by MRI
Brain Regions affected in MSA
0.02
0.00
0.02
Change from BL
0.04
Cerebellar Dentate Nucleus
Pallidum
0.02
**
Change from BL
Change from BL
0.06
Putamen
0.01
0.00
-0.01
0.02
Change from BL
Substantia Nigra
0.01
0.00
-0.01
0.01
0.00
-0.01
-0.02
-0.02
-0.02
6M
12M
-0.02
6M
12M
6M
12M
6M
12M
Statistically significant increase in iron over 12 months in the substantia nigra
** p < 0.01
16
Optimizing MRI Methods to Measure Brain Volumes
•
•
•
•
Multiple System Atrophy = atrophy (shrinking) of brain structures
Routine MRI are analyzed in 2 dimensions (2D)
We are interested in measuring brain volume (in 3D)
Needed a new method to measure volumes in MSA affected areas
Method Development
• Neuroradiologist manually traced 2D images for each
bioMUSE subject
• 2D MRI à 3D rendering à measure volume
•
Human time: 10 hours per MRI
• Bioengineer employed Machine Learning/AI to teach
computer to do the same
•
Computer time: 5 minutes per MRI
2D image
3D rendering
Allows measurement of brain volumes with precision in all Phase 2 participants
17
BioMUSE: Change in Brain Volume by MRI
Brain Regions affected in MSA
Cerebellum
Putamen
Brainstem
Pallidum
0
-3
-6
-2
**
-4
-6
12M
**
-3
-6
-9
-12
-8
6M
0
6M
12M
% Change from BL
**
*
**
% Change from BL
0
% Change from BL
% Change from BL
**
0
**
-3
-6
-9
-12
6M
12M
6M
12M
Statistically significant decreases in brain volume observed in all regions
at 12 months and in 3 of 4 regions at 6 months
* p < 0.05
** p < 0.01
18
BioMUSE: Change in Brain Volume by MRI
Brain Atrophy in MSA
MSA
PD
0
**
-2
**
-4
-6
% Change from BL
Combine volume of these
4 regions affected in MSA
% Change from BL
0
-2
-4
-6
6M
12M
6M
12M
New Imaging Biomarker
MSA Volume Index
19
BioMUSE Summary
• Observational Study in MSA
• Goals: improve patient selection and choose endpoints for Phase 2
• Iron content: Significant increase in iron observed at 12 months in one brain
region (s. nigra)
• Brain volume: Significant decrease in volume observed over 12 months in all
four MSA regions
v Novel Imaging Biomarker: MSA Volume Index
20
Implications of bioMUSE Data on ATH434-202 Study
21
Endpoint Selection in Treatment Trials
Biomarker Endpoint Selection
Relevant to
underlying disease
Tracks with disease Preclinical indication
progression
of drug effect
We target endpoints with the largest change over the planned
study period to more readily demonstrate a drug effect
22
ATH434-202 Key Study Endpoints
Primary Endpoint
Change in MSA Volume Index by MRI at 12
months
• Based on the significant decrease in volume in
relevant brain regions in MSA
Secondary Endpoint
Change in Iron content in the substantia nigra
by MRI at 12 months
• Based on the significant increase in iron in
relevant brain region in MSA
23
Key Milestones
ATH434-201
Phase 2 Trial
Topline Data
ATH434-202
Preliminary
6 mo Data
BioMUSE
Data
ATH434-201
Phase 2 Trial
Study Complete
ATH434
MoA data
Scientific Meeting
Presentations
Jan 24
Feb 24
Mar 24
Apr 24
May 24
Jun 24
Jul 24
Aug 24
Sep 24
Oct 24
Nov 24
Dec 24
Jan 25
Feb 25
24
Daniel Claassen, M.D., M.S.
Professor of Neurology
Vanderbilt University Medical Center
Research focus: Neuroimaging/Therapeutics
Principal Investigator of bioMUSE
Coordinating Investigator of the ATH434-201
Clinical Trial
25
ASX:ATH | NASDAQ:ATHE
Share your feedback
Discover